HIMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Hims & Hers Health Inc (HIMS) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 to invest. The stock shows bearish technical indicators, weak financial performance, and negative sentiment from analysts and news. While hedge funds are buying, there are no strong positive catalysts to justify a buy at this time. Holding off on investment until clearer growth trends emerge is recommended.
The stock is showing bearish momentum with moving averages in a downward trend (SMA_200 > SMA_20 > SMA_5). RSI is at 19.822, indicating oversold conditions, but this alone does not confirm a reversal. The MACD histogram is positive at 0.156, but the overall trend remains weak. Key support is at 14.272, and resistance is at 16.732.
Hedge funds have increased their buying by 211.82% over the last quarter. The company reported strong subscriber growth and exceeded EPS estimates for Q4 2025.
The stock has dropped 70% over the past year due to competition concerns from Novo Nordisk's GLP-1 weight loss drugs. Analysts have downgraded the stock and lowered price targets significantly, citing disappointing Q4 results, weak Q1 guidance, and increased regulatory risks. Insider trading trends are neutral, and there is no recent congress trading data.
In Q4 2025, revenue increased by 28.41% YoY to $617.82 million, but net income dropped by 20.84% YoY to $20.6 million. EPS fell by 27.27% YoY to $0.08, and gross margin decreased by 6.34% YoY to 71.94%. The company provided cautious revenue guidance for Q1 2026, with a projected decline of 8.8% in sales.
Analysts have a predominantly negative outlook on HIMS. Multiple firms downgraded the stock or lowered price targets significantly. Concerns include weak Q1 guidance, slowing revenue growth, regulatory risks, and uncertainty around the company's GLP-1 franchise.
